Propel Bio Management, LLC 13F holdings, Q2 2026
Holdings as of June 30, 2026 · filings on SEC EDGAR · this is the latest filing on record
Propel Bio Management, LLC disclosed 29 US equity positions worth $191.1m in its Q2 2026 13F filing. The largest position was PAGPEUR at 16.2% of the reported book, followed by ACHV and CORT. Against the Q1 2026 filing, it opened 4 new positions, added to 11 and reduced 10 among the top 29 holdings.
What did Propel Bio Management, LLC own in Q2 2026? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2026 |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HOLDINGS LP-CL | 16.2% | $30.9m | 1,272,360 | 0% | held | |
| 2 | ACHV ACHIEVE LIFE SCIENCES INC | 13.8% | $26.3m | 4,034,018 | 7% | added | |
| 3 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 6.2% | $11.9m | 136,499 | -8% | reduced |
| 4 | PHAT PHATHOM PHARMACEUTICALS I | Healthcare | 6.0% | $11.4m | 1,050,358 | 25% | added |
| 5 | DCTH DELCATH SYSTEMS INC | 5.7% | $11.0m | 871,460 | -11% | reduced | |
| 6 | MIST MILESTONE PHARMACEUTICALS | 5.2% | $10.0m | 7,429,590 | 80% | added | |
| 7 | CMPS COMPASS PATHWAYS PLC | Healthcare | 4.2% | $8.1m | 573,086 | -23% | reduced |
| 8 | KYTX KYVERNA THERAPEUTICS INC | 4.1% | $7.9m | 883,198 | 37% | added | |
| 9 | ARTV ARTIVA BIOTHERAPEUTICS IN | 3.5% | $6.8m | 696,436 | 376% | added | |
| 10 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.2% | $6.1m | 983,070 | -26% | reduced |
| 11 | AQST AQUESTIVE THERAPEUTICS IN | 3.1% | $6.0m | 1,442,397 | 103% | added | |
| 12 | PALI PALISADE BIO INC | Healthcare | 2.8% | $5.4m | 2,582,388 | 132% | added |
| 13 | IMUX IMMUNIC INC | 2.6% | $5.0m | 325,022 | – | new | |
| 14 | IVA INVENTIVA SA - ADR | 2.5% | $4.8m | 1,281,212 | 77% | added | |
| 15 | SABS SAB BIOTHERAPEUTICS INC | 2.2% | $4.2m | 1,076,578 | 6% | added | |
| 16 | OBIO ORCHESTRA BIOMED HOLDINGS | 2.0% | $3.9m | 896,701 | 0% | held | |
| 17 | CLDX CELLDEX THERAPEUTICS INC | Healthcare | 2.0% | $3.9m | 103,695 | -21% | reduced |
| 18 | ZVRA ZEVRA THERAPEUTICS INC | 1.9% | $3.6m | 253,544 | -10% | reduced | |
| 19 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 1.8% | $3.5m | 357,966 | -6% | reduced |
| 20 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 1.8% | $3.4m | 252,654 | -34% | reduced |
| 21 | OVID OVID THERAPEUTICS INC | Healthcare | 1.6% | $3.0m | 1,115,538 | 21% | added |
| 22 | EYPT EYEPOINT INC | Healthcare | 1.4% | $2.7m | 191,745 | -11% | reduced |
| 23 | UPB UPSTREAM BIO INC | 1.3% | $2.4m | 350,389 | 3% | added | |
| 24 | SCYX SCYNEXIS INC | 1.2% | $2.2m | 543,478 | – | new | |
| 25 | SLN SILENCE THERAPEUTICS PLC | 1.1% | $2.1m | 191,733 | – | new | |
| 26 | LONA LEONABIO INC | 0.7% | $1.4m | 149,279 | 0% | held | |
| 27 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.7% | $1.3m | 43,798 | 0% | held |
| 28 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.6% | $1.1m | 70,380 | -18% | reduced |
| 29 | SGMT SAGIMET BIOSCIENCES INC-A | Healthcare | 0.5% | $973.0k | 125,878 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.